Intratumor Injection of Thermosensitive Polypeptide with Resveratrol Inhibits Glioblastoma Growth

Yi, Guoqing; Liu, Huan-Dong; Sun, Fenglei; Du, Ruxu; Kong, Jun; Wang, Hong; Cheng, Huilin; Wang, Guihuai; Gao, Feng; Liang, Ping

doi:10.1089/ten.tec.2022.0207

Cited by 4 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most recently, Yi et al evaluated a novel anti-GBM strategy based on a combined administration of interferon-elastin-like polypeptide (IFN-ELP(V)) and resveratrol. IFN-ELP(V) is a slow-release, biodegradable, thermosensitive fusion protein designed for intratumor injection, whereas resveratrol was administered as an intraperitoneal injection [73]. The results of this study suggested that IFN-ELP(V) can create a reservoir in the tumor, in which IFN is continuously released to produce a powerful in situ anti-tumor immune response, whereas resveratrol synergistically augments the anti-tumor effect.…”

Section: Phytocompound-based Immunotherapymentioning

confidence: 91%

“…Using a mouse model, the authors showed that the intratumor injection of IFN-ELP(V) combined with the intraperitoneal injection of resveratrol was effective in delaying GBM growth. Such an approach provides a novel and effective therapeutic strategy for tumors, especially those that are unsuitable for surgical resection [73].…”

Section: Phytocompound-based Immunotherapymentioning

confidence: 99%

See 1 more Smart Citation

New Avenues and Major Achievements in Phytocompounds Research for Glioblastoma Therapy

Majchrzak-Celińska,

Studzińska-Sroka

2024

Molecules

View full text Add to dashboard Cite

Phytocompounds have been evaluated for their anti-glioblastoma actions for decades, with promising results from preclinical studies but only limited translation into clinics. Indeed, by targeting multiple signaling pathways deregulated in cancer, they often show high efficacy in the in vitro studies, but their poor bioavailability, low tumor accumulation, and rapid clearance compromise their efficacy in vivo. Here, we present the new avenues in phytocompound research for the improvement of glioblastoma therapy, including the ways to enhance the response to temozolomide using phytochemicals, the current focus on phytocompound-based immunotherapy, or the use of phytocompounds as photosensitizers in photodynamic therapy. Moreover, we present new, intensively evaluated approaches, such as chemical modifications of phytochemicals or encapsulation into numerous types of nanoformulations, to improve their bioavailability and delivery to the brain. Finally, we present the clinical trials evaluating the role of phytocompounds or phytocompound-derived drugs in glioblastoma therapy and the less studied phytocompounds or plant extracts that have only recently been found to possess promising anti-glioblastoma properties. Overall, recent advancements in phytocompound research are encouraging; however, only with more 3D glioblastoma models, in vivo studies, and clinical trials it is possible to upgrade the role of phytocompounds in glioblastoma treatment to a satisfactory level.

show abstract

Section: Phytocompound-based Immunotherapymentioning

confidence: 91%

Section: Phytocompound-based Immunotherapymentioning

confidence: 99%

New Avenues and Major Achievements in Phytocompounds Research for Glioblastoma Therapy

Majchrzak-Celińska,

Studzińska-Sroka

2024

Molecules

View full text Add to dashboard Cite

show abstract

“…A) Macroscale materials are linked to which types of materials have been formed. Generally, most macroscale materials can form more different morphologies of materials. ,,,,,,,− B) Nanoscale materials have been linked to material types which have been formed. ,,− …”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Genetic Functionalization of Protein-Based Biomaterials via Protein Fusions

Mendes,

Faulk,

Kaparthi

et al. 2024

Biomacromolecules

View full text Add to dashboard Cite

Proteins implement many useful functions, including binding ligands with unparalleled affinity and specificity, catalyzing stereospecific chemical reactions, and directing cell behavior. Incorporating proteins into materials has the potential to imbue devices with these desirable traits. This review highlights recent advances in creating active materials by genetically fusing a selfassembling protein to a functional protein. These fusion proteins form materials while retaining the function of interest. Key advantages of this approach include elimination of a separate functionalization step during materials synthesis, uniform and dense coverage of the material by the functional protein, and stabilization of the functional protein. This review focuses on macroscale materials and discusses (i) multiple strategies for successful protein fusion design, (ii) successes and limitations of the protein fusion approach, (iii) engineering solutions to bypass any limitations, (iv) applications of protein fusion materials, including tissue engineering, drug delivery, enzyme immobilization, electronics, and biosensing, and (v) opportunities to further develop this useful technique.

show abstract

An Overview of the Cancer Targeting Attributes of the Elastin Like Polypeptide Nano‐Carriers: Discerning Active and Passive Modes

Goel,

Gulwani,

Upadhyay

et al. 2024

Advanced Therapeutics

View full text Add to dashboard Cite

Since the 1940s, generalized cytotoxic therapy has been a valuable tool in cancer treatment. Over the years, there's been a significant increase in developing potential cytotoxic drugs. However, little progress has been made in enhancing patients' quality of life. The therapeutic index is limited due to the drug's poor solubility and lack of selectivity. Various carriers have been explored for drug delivery to enhance efficacy. Yet, there's a gap for a versatile delivery system that can adjust to specific drug and application requirements. Here, a multifaceted drug delivery platform based on a genetically engineered nature‐inspired polymer, elastin‐like polypeptide (ELP) is introduced. This technology enables the customization of the polymeric vehicle's physicochemical characteristics to suit the needs of a specific drug and application. The review highlights ELP's advantages in cancer targeting, such as site‐specificity, controlled release, biocompatibility, and extended plasma circulation. For the first time, ELP‐based drug delivery into passive and active targeting for better comprehension of its adaptability is classified. Moreover, numerous opportunities for loading different types of drugs onto the polymer are outlined. Finally, the polymer's efficacy in delivery across multiple cancer types, underscoring the wide spectrum of ELP‐based cancer drug delivery is precisely described.

show abstract

Intratumor Injection of Thermosensitive Polypeptide with Resveratrol Inhibits Glioblastoma Growth

Cited by 4 publications

References 21 publications

New Avenues and Major Achievements in Phytocompounds Research for Glioblastoma Therapy

New Avenues and Major Achievements in Phytocompounds Research for Glioblastoma Therapy

Genetic Functionalization of Protein-Based Biomaterials via Protein Fusions

An Overview of the Cancer Targeting Attributes of the Elastin Like Polypeptide Nano‐Carriers: Discerning Active and Passive Modes

Contact Info

Product

Resources

About